London-based personalized supplements startup Vionic It raised $15 million in a Series B funding round.
Bioniq uses biomarker data to tailor supplements for its customers. Over the past decade, Bioniq has built the largest proprietary biochemistry database of its kind, leveraging blood test data from customers across five continents. Powered by AI, Bioniq’s patent-pending algorithms assess an individual’s height, weight, age, lifestyle and health goals to accurately identify micronutrient imbalances and create customized supplement formulas that help optimize health.
The oversubscribed round was led by lead investors HV Capital and Unbound, both of which are leading European venture capital firms. The company is valued at $75 million and will use the funds to continue disrupting the dietary supplements market and further expand its global market share. Bioniq will focus on product development, including consolidating its global research network, expanding its markets, operations and talent in the US and the Middle East, and implementing its enterprise platform for medical, health and sports institutions.
Bioniq’s approach to tailored solutions based on personal data and health goals has seen significant growth over the past 12 months, with the highest demand coming from the US market, which now accounts for over 50% of the company’s customer base and has grown by over 500% in some regions over the past two quarters. Bioniq’s ability to provide quantifiable before-and-after snapshots of users’ nutritional needs and optimization progress is one of its greatest assets in partnerships with leading medical and sports organizations such as Lanserhof and UFC.
Bioniq has become the product of choice for many of the world’s top athletes, including Manchester United’s Diogo Dalot and former NBA All-Star Andrei Kirilenko, who have used Bioniq for years to optimize their micronutrient levels to enhance performance and recovery.
“Over the past six years, nutritional supplements have entered a new era, where it has become clear that a one-size-fits-all solution is simply ineffective,” said Vadim Fedotov, co-founder and CEO of Vionic.
“Everyone’s health journey is unique and fluid. Our customers
“Adaptable products that provide evolving support for an individual’s health goals. Our AI-driven approach and extensive biochemistry database allow us to create customized supplements that deliver quantifiable results and address the specific needs of individuals. Not only are we meeting consumer demand, but we are setting new standards in the industry by making our process and results transparent to users.”
Bioniq PRO offers the highest level of personalization for high performers and health-conscious individuals, incorporating blood biomarker data into its algorithms and offering the option to upload existing blood test results into the system to get recommendations based on a global data repository, or to book a blood test with Bioniq via a partner lab, where the blood biomarker data will be analyzed to assess.
We address these issues by understanding your current nutritional status, identifying imbalances, and providing you with a personalized daily supplement regimen. 11 Nutrition Consultations also provide an opportunity to discuss your unique needs and next steps with a registered dietitian.
Bioniq GO leverages the company’s same proprietary database to provide users with a more accessible option where, based on a questionnaire, an AI algorithm prompts users to recommend a unique supplement blend based on their answers and previous users’ blood biomarker data.
All Bioniq supplements are Swiss made, pharmaceutical grade and precision processed.
Microdosing addresses bio-individual needs and deficiencies. Each formula is created specifically for the individual user and features a unique combination of antioxidants, vitamins, minerals, phytonutrients, amino acids and prebiotic fiber. Delivered in patented prebiotic guar granules rather than traditional tablets or capsules, the product is designed to mimic the way the body digests food, minimizing nutrient competition and maximizing bioavailability.
“Vioniq’s exceptional growth is a testament to the company’s innovative approach to high-quality personalized health solutions that professional athletes around the world rely on,” said David Kuczek, general partner at HV Capital. “With sales in more than 60 countries, the majority of which are from North America, the most significant health solutions market in the world, Vioniq is well positioned to continue its rapid expansion trajectory.”
“Vioniq’s innovative approach to nutrition is based on the idea that each person has different nutritional needs and deficiencies, and generic multivitamins are not sufficient to address them.
“We are impressed with Bioniq’s vision and technology and believe they are revolutionizing the supplement industry with their personalized, science-based approach. We are excited to support their business as it grows and expands,” said Shrabin Mittal, CEO of Unbound.
